Indication
Neurofibromatosis type 1 with plexiform neurofibromas
Neurofibromatosis type 1 with plexiform neurofibromas refers to an autosomal dominant genetic tumor predisposition syndrome characterized by the development of complex, benign peripheral nerve sheath tumors. Read more about Neurofibromatosis type 1 with plexiform neurofibromas
3 drugs 3 manufacturers
Drugs that treat it
Common Neurofibromatosis type 1 with plexiform neurofibromas therapies.
KOSELUGO (selumetinib sulfate)
GOMEKLI (mirdametinib)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNeurofibromatosis type 1 with plexiform neurofibromas refers to an autosomal dominant genetic tumor predisposition syndrome characterized by the development of complex, benign peripheral nerve sheath tumors.
Driven by pathogenic variants in the *NF1* gene that lead to loss of the tumor suppressor neurofibromin and hyperactivation of the RAS-MAPK signaling pathway, these tumors arise primarily from Schwann cells and expand along single or multiple nerve fascicles and branches.
Plexiform neurofibromas typically manifest in early childhood, affecting deep or superficial nerves across various anatomic sites.
Because they infiltrate surrounding tissues, they frequently cause severe pain, motor deficits, spinal or skeletal deformities, and airway or vascular compromise, while also harboring a lifelong risk of malignant transformation into peripheral nerve sheath tumors.
- nih.gov
Neurofibromatosis type 1 with plexiform neurofibromas refers to an autosomal dominant genetic tumor predisposition syndrome characterized by the development of complex, benign peripheral nerve sheath tumors Because they infiltrate surrounding tissues, they frequently cause severe pain, motor deficits, spinal or skeletal deformities, and airway or vascular compromise, while also harboring a lifelong risk of malignant transformation into peripheral nerve sheath tumors
- nih.gov
Neurofibromatosis type 1 with plexiform neurofibromas refers to an autosomal dominant genetic tumor predisposition syndrome characterized by the development of complex, benign peripheral nerve sheath tumors Driven by pathogenic variants in the *NF1* gene that lead to loss of the tumor suppressor neurofibromin and hyperactivation of the RAS-MAPK signaling pathway, these tumors arise primarily from Schwann cells and expand along single or multiple nerve fascicles and branches
- nih.gov
Neurofibromatosis type 1 with plexiform neurofibromas refers to an autosomal dominant genetic tumor predisposition syndrome characterized by the development of complex, benign peripheral nerve sheath tumors Because they infiltrate surrounding tissues, they frequently cause severe pain, motor deficits, spinal or skeletal deformities, and airway or vascular compromise, while also harboring a lifelong risk of malignant transformation into peripheral nerve sheath tumors
- nih.gov
Driven by pathogenic variants in the *NF1* gene that lead to loss of the tumor suppressor neurofibromin and hyperactivation of the RAS-MAPK signaling pathway, these tumors arise primarily from Schwann cells and expand along single or multiple nerve fascicles and branches
- nih.gov
Plexiform neurofibromas typically manifest in early childhood, affecting deep or superficial nerves across various anatomic sites Because they infiltrate surrounding tissues, they frequently cause severe pain, motor deficits, spinal or skeletal deformities, and airway or vascular compromise, while also harboring a lifelong risk of malignant transformation into peripheral nerve sheath tumors
- cancer.gov
Plexiform neurofibromas typically manifest in early childhood, affecting deep or superficial nerves across various anatomic sites
Personalize your experience
Follow Neurofibromatosis type 1 with plexiform neurofibromas and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.